{"id":341164,"date":"2026-11-06T00:53:36","date_gmt":"2026-11-05T19:23:36","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-q2-results-fy27-pat-52-crore\/"},"modified":"2026-11-06T00:53:36","modified_gmt":"2026-11-05T19:23:36","slug":"symbiotec-pharmalab-q2-results-fy27-pat-52-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-q2-results-fy27-pat-52-crore\/","title":{"rendered":"SYMBIOTEC PHARMALAB Q2 Results FY27: Net Profit Jumps 267.85% QoQ to Rs 51.72 Cr, Revenue Rs 279.93 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

SYMBIOTEC PHARMALAB Q2 Results FY27 were declared on 5 November 2026 on a consolidated basis, covering the July to September 2026 quarter. Revenue rose 28.32% QoQ to Rs 279.93 Cr, while net profit moved up 267.85% QoQ to Rs 51.72 Cr. These quarterly results show QoQ growth across revenue, Operating Profit of Rs 91.51 Cr and net profit, with net profit growing fastest.<\/p>\n<\/div>\n

SYMBIOTEC PHARMALAB LTD<\/a> (SYMBIOTEC) Q2 Results FY27 announced on 5 November 2026, covering the company’s financial performance for the July to September quarter. The company reported consolidated revenue of Rs 279.93 Cr and PAT of Rs 51.72 Cr, and the results date of 5 November 2026 anchors every comparison below. SYMBIOTEC PHARMALAB Q2 Results FY27 is measured against the previous quarter, on the consolidated results as filed.<\/p>\n

This SYMBIOTEC PHARMALAB Q2 Results results analysis covers the financial highlights, the business drivers, the outlook and the risks, in that order. The results analysis begins with the Financial Highlights table, which sets each reported line beside its previous-quarter figure.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n